Skip to content
GLP-1 Desk
Menu

Head-to-head dispatch

1st Optimal vs Telos Rx

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Dispatch #502
1st Optimal

1st Optimal is a Michigan-based telehealth and functional-medicine platform offering GLP-1 weight loss medications, including semaglutide and tirzepatide, as once-weekly injections or daily oral tablets.

Marked down on: No public monthly pricing disclosed

vs
Dispatch #19Desk pick
Telos Rx

The broadest published catalog in the ranking — compounded GLP-1s plus oral and microdosed tirzepatide, PT-141, intranasal NAD+, and recovery peptides — all compounded and not FDA-approved.

$99/mo (injectable, month-to-month; the $49 headline is only the FIRST month of the 12-month prepaid ORAL plan, which renews at $129/mo billed every 48 weeks) sema · $139/mo injectable · $129/mo oral · $116/mo microdosed (microdosing is tirzepatide, not semaglutide) tirz

Marked down on: Everything is compounded and not FDA-approved — including all peptides and the NAD+ spray

Telos Rx takes this head-to-head with the higher Desk Score, 85/100 (B) against 41/100 (C) for 1st Optimal. 1st Optimal still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

1st Optimal

41/100

C

Overall

Telos Rx

85/100

B

Price transparency

20
74

State access

24
62

Molecule range

51
98

Onboarding speed

40
84

Support responsiveness

82
76

Licensing & trust

65
88

The spec sheet

Field1st OptimalTelos Rx
SemaglutideNot listed on 1st Optimal's site (checked July 26, 2026)$99/mo (injectable, month-to-month; the $49 headline is only the FIRST month of the 12-month prepaid ORAL plan, which renews at $129/mo billed every 48 weeks)
TirzepatideNot listed on 1st Optimal's site (checked July 26, 2026)$139/mo injectable · $129/mo oral · $116/mo microdosed (microdosing is tirzepatide, not semaglutide)
CoverageNot listed on 1st Optimal's site (checked July 26, 2026)Not listed on Telos Rx's site
Brand-nameCompounded onlyCompounded only
Oral optionYesYes
Best forPatients wanting GLP-1 therapy within a lab-driven functional-medicine program.Patients who want GLP-1 care alongside peptides, NAD+, and sexual-health options on one certified platform, with a needle-free oral or microdosed route.
Desk Score41/100C85/100B

The verdict

Desk pick — Telos Rx

Telos Rx takes this head-to-head with the higher Desk Score, 85/100 (B) against 41/100 (C) for 1st Optimal. 1st Optimal still holds its ground where its strengths line up with yours.

Choose 1st Optimal if…

Patients wanting GLP-1 therapy within a lab-driven functional-medicine program.

Choose Telos Rx if…

Patients who want GLP-1 care alongside peptides, NAD+, and sexual-health options on one certified platform, with a needle-free oral or microdosed route.

$99/mo (injectable, month-to-month; the $49 headline is only the FIRST month of the 12-month prepaid ORAL plan, which renews at $129/mo billed every 48 weeks) sema · $139/mo injectable · $129/mo oral · $116/mo microdosed (microdosing is tirzepatide, not semaglutide) tirz

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: 1st Optimal · Telos Rx.

Also here

CoreAge Rx tops every dispatch at 94/100

Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: one price at every dose, both molecules, all 50 states — but the $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.